The Turkish Journal of Pediatrics
[Mail to Editor ]
Association between genotype, clinical presentation, and severity of congenital adrenal hyperplasia: a review
Abdulmoein E. Al-Agha1, Ali H. Ocheltree2, Masha’el D. Al-Tamimi1
1Department of Pediatrics, King Abdul-Aziz University Hospital, Faculty of Medicine, Jeddah and 2 Department of Internal
Medicine, North West Armed Forces Hospital, Tabuk, Kingdom of Saudi Arabia. E-mail: email@example.com
|Congenital adrenal hyperplasia (CAH) applies to a family of inherited disorders
of steroidogenesis caused by an abnormality in one of the five enzymatic steps
necessary in the conversion of cholesterol to cortisol. The enzyme defects are
transmitted as an autosomal recessive trait. Patients with a “classical” form
of CAH usually present during the neonatal and early infancy period with
adrenal insufficiency, which could be associated with a salt- losing pathology.
Females usually have genital ambiguity. Approximately 67% of classical CAH
patients are classified as “salt-losing”, while 33% have “non-salt-losing” or
the “simple-virilizing” form, reflecting the degree of aldosterone deficiency.
Non-classic 21-hydroxylase deficiency (NC 21-OHD) refers to the condition
in which partial deficiencies of 21-hydroxylation produce less extreme
hyperandrogenemia and milder symptoms. Females do not demonstrate genital
ambiguity at birth. The gene for adrenal 21-hydroxylase, CYP21, is located on
chromosome 6p in the area of human leukocyte antigen (HLA) genes. Specific
mutations may be associated with a certain degree of enzymatic compromise
and the clinical form of 21-hydroxylase deficiency (21-OHD). NC 21-OHD
patients are predicted to have mild mutations on both alleles and one severe
or one mild mutation of the 21-OH locus (compound heterozygote). This
review aims to describe the association between the genotype and clinical
presentations and severity of CAH.|
congenital adrenal hyperplasia, adrenal insufficiency, genital ambiguity,
|Congenital adrenal hyperplasia (CAH) refers
to a group of autosomal recessive disorders
with defects in the biosynthesis of the cortisol
hormone. The synthesis of other steroids, such
as mineralocorticoids and adrenal/gonadal sex
steroids, may also be affected (Fig. 1). The
low level of cortisol stimulates the pituitary
gland to release adrenocorticotropic hormone
(ACTH). This chronic elevation in ACTH
causes hyperplasia of the adrenal cortex, giving
the characteristic enlargement of the gland.
The clinical presentation of the various forms
of CAH depends on the following: 1) the
affected enzyme, 2) the residual enzymatic
activity, 3) consequences of deficiencies of the
end products, and 4) hormonal effects of the
elevated precursors. The defective conversion
of 17-hydroxyprogesterone to 11-deoxycortisol
accounts for more than 90% of cases of CAH.
This conversion is mediated by 21-hydroxylase,
which is also referred to as CYP21A2.
Patients with the “classical” form present during
the neonatal period and early infancy with
adrenal insufficiency with or without salt-losing
or as toddlers with virilization. The “classical”
form is the most severe form of CAH due
to CYP21A2 deficiency in particular. Females
usually have genital ambiguity. Approximately
67% of classical CAH patients are classified as
“salt-losing”, while 33% are classified as “nonsalt-
losing” or “simple-virilizing”, reflecting the
degree of aldosterone deficiency.
“Non-classical” or late-onset CYP21A2
deficiency presents later in life with signs of
androgen excess and without neonatal genital
ambiguity. Clinical features in childhood may
include premature pubarche and accelerated bone age; adolescent and adult females may be
presented with hirsutism, menstrual irregularity,
infertility, and acne. Some patients with nonclassic
CAH remain asymptomatic-.
| ||Figure 1. A scheme of the pathways of steroidogenesis, including an elaboration of the biological process by which
steroids are generated from cholesterol and transformed into other steroids.|
Humans have two CYP21A genes, a nonfunctional
pseudo-gene (CYP21A1 or CYP21P)
and the active gene (CYP21A2 or CYP21), and
both are located on the 35-kilobase region
of chromosome 6p21.3 within the major
histocompatibility locus. The pseudo-gene
produces a truncated enzyme with no activity
because it lacks eight bases from codons 110
to 112, resulting in a stop codon-.
The two CYP21A genes are more than 90%
homologous. This high degree of homology
facilitates recombination events during meiosis,
with consequent exchanges of segments of
DNA between the two genes.
· Unequal crossover exchanges leading to
deletions of large segments of the CYP21P
gene or a non-functioning CYP21P/CYP21
fusion gene (macro-conversion) account for
about 20% of CYP21A2 mutations described
· Other hybrid CYP21A1/CYP21A2 gene
products have decreased, not halted, enzyme
activity. A patient who is heterozygous for
this and with a typical large gene deletion
may have non-classic CYP21A2 deficiency.
· Altered regions of the CYP21A1 gene can
be transferred to the CYP21A2 gene through
non-reciprocal gene conversion. This is a
process by which a segment of genetic
material is transferred to a closely related
gene, altering its sequence,.
· These micro-conversion events represent
acquisition of smaller segments of the
CYP21A1 sequence by the CYP21A2 gene
and result in deleterious point mutations
that reduce enzyme activity. They are present
in about 70% of patients with defined
· Eighteen gene conversion mutations account
for nearly all affected alleles in various
ethnic groups3,13-15. The remaining 5% of
patients with defined abnormalities have one
or more of the 60 point mutations,-.
Among 130 Brazilian patients, 20% did not
have a known mutation, suggesting that
other mutations occur. A novel missense
mutation was subsequently identified in
three patients with suggestion of a founder
effect. No mutation was detected in the
entire coding region of the gene and up to 1
kb of the 5'-flanking promoter region of the
gene in a Mexican and three Japanese patients,
suggesting that more distant mutations may
occur,. It is not always possible to predict
the phenotype of these patients from the
specific mutation(s) of the CYP21A2 gene,
but there are general correlations between
genotype and phenotype,-. Patients with
CYP21A2 mutations can be divided into
groups according to the predicted effect of the
mutation on 21-hydroxylase enzymatic activity,
as determined by site-directed mutagenesis and
expression and in vitro analysis of enzymatic
The salt-losing form of the disorder is most
often associated with large deletions or intron
2 mutations that affect splicing and result in
no enzyme activity, while patients with the
simple virilizing form have low but detectable
enzyme activity (i.e., 1-2%) that supports
sufficient aldosterone and glucocorticoid
production. This most commonly results from
point mutations leading to non-conservative
amino-acid substitutions such as Ile172Asp.
Women with the non-classic form may be
either compound heterozygotes (with a classic
mutation and a variant allele) or heterozygotes
with two variant alleles, allowing for 20-60%
of normal enzymatic activity (e.g., with point
mutations leading to conservative amino acid
substitutions such as Val281Leu). Patients who
are compound heterozygotes for two different
CYP21A2 mutations usually have the phenotype
associated with the less severe of the two
genetic defects. Heterozygotes may have mild
biochemical abnormalities, but no clinically
important endocrine disorder,. Despite these
general correlations, the CYP21A2 deficiency
phenotype does not always correlate precisely
with the genotype,, suggesting that other
genes influence the clinical manifestations. In
general, there appears to be high concordance
rates between genotype and phenotype in
patients with the most severe and the mildest
forms of the disease, but less genotypephenotype
correlation in moderately affected
Genetics Deficiencies of Uncommon Causes
1). Deficiency of 17-alpha-hydroxylase
Deficiency of 17-alpha-hydroxylase activity is
a rare form of CAH. Approximately 120 cases
have been reported,. However, prevalence
may be higher, particularly in Brazil, where the
founder effects account for over 80% of mutant
alleles caused by only two mutations,.
The CYP17 gene encodes an enzyme that
has both 17-hydroxylase and 17, 20-lyase
(desmolase, or side-chain cleavage) activities.
The hydroxylation of C17 of progesterone is
required for cortisol production as well as for
synthesis of androgens and estrogens. Lyase
activity is required for synthesis of androgens
and their derivatives, the estrogenic C18
steroids. Although CYP17 has both activities in
vitro, human CYP17 deficiency syndromes have
been observed in which patients apparently
lack only 17-hydroxylase deficiency or only 17,
20-lyase deficiency,. Most patients, however,
have a combined defect.
2). 17-hydroxylase defect:
Reduction of cortisol production by the
17-hydroxylase defect results in an increased
ACTH secretion. Therefore, there is an
increased production of 11-deoxysteroids
including corticosterone, mineralocorticoids,
11-deoxycorticosterone, and 18-hydroxydeoxycorticosterone,.
Thus, one consequence
of 17-alpha-hydroxylase deficiency is
mineralocorticoid excess. The ensuing volume
expansion inhibits rennin release and therefore
the synthesis of aldosterone.
3). 17, 20 lyase defect:
Reduction of androgen production by
impairment of 17, 20 lyase activity leads to
combined androgen and estrogen deficiency
because only androgens can be aromatized
to form estrogens. 17-alpha-hydroxylase
activity (CYP17) is also expressed in the
gonads so that gonadal steroidogenesis is also
decreased in patients with this disorder. CYP17
deficiency like other forms of CAH appears to
be inherited as an autosomal recessive trait.
Several cases were reported, and they were
the product of consanguineous marriages and obligate heterozygotes with mild defects
in CYP17 activity that can be revealed by
ACTH stimulation,,. Nearly 40 different
mutations in the CYP17 gene, which is located
on chromosome 10, have been defined at the
molecular level. These include small insertions
that disrupt the normal reading frame of the
gene and lead to premature termination,,
deletions of single codons, deletions of several
codons, large deletions with insertions of
foreign DNA, and a variety of nonsense or
missense mutations of CYP17 that produce
stop codons, impair CYP17 enzyme activity,
or alter splice sites-. Two mutations have
been described in splice receptor sites. There
may be factors other than the CYP17 genotype
that determine the phenotype of individuals
with CYP17 deficiency. In a study of 24
patients from 19 families in Brazil, the majority
(20/24) had one of two mutations, both of
which were completely inactive in vitro].
However, for patients with the same mutation,
the phenotype was sometimes variable. As
an example, of three male (XY karyotyping)
patients with an R362C mutation, the first
presented at birth with ambiguous genitalia,
the second had female external genitalia and
normokalemia, and the third had the classical
presentation (hypertension, hypokalemia, and
pubertal delay). A rare variant, with combined
CYP21A2 and CYP17 deficiency, has been
described in both boys and girls and appears
to be due to mutations in the gene encoding
oxidoreductase, not the CYP17 and CYP21A2
4). 3-beta-hydroxysteroid dehydrogenase
3-beta-hydroxysteroid dehydrogenase deficiency
is a rare form of CAH, in which synthesis of
all steroid hormones is impaired as 3-betahydroxysteroid
catalyzes the rearrangement of the double bonds
in the ring (A) of steroids and conversion of a
hydroxyl group at the 3 position to a keto group.
Deficiency of this enzyme results in decreased
synthesis of cortisol, aldosterone, androgens, and
estrogens. Cortisol deficiency leads to increased
ACTH secretion and therefore accumulation
of excessive amounts of steroid precursors
with the delta-5, 3-hydroxy configuration
(e.g., delta-5-pregnenolone, 17-alphahydroxypregnenolone,
(DHEA), and dehydroepiandrosterone-sulfate
(DHEAS). The decreased enzyme activity
in this disorder is caused by mutations in
the 3-beta-hydroxysteroid dehydrogenase II
gene. In patients with the severe, salt-wasting
form, nonsense mutations introducing codons,
insertion and deletion mutations causing frame
shifts-, and point mutations that alter enzyme
function have all been described. On the other
hand, all patients without salt-wasting have had
missense mutations causing single amino acid
substitutions that reduced the affinity of the
enzyme for substrates or cofactors. The 3-betahydroxysteroid
dehydrogenase type 1 gene,
which is normally expressed in the placenta and
peripheral tissues, is intact in these patients,
providing an explanation for the near normal or
even elevated serum concentrations of delta-4
steroids (such as 17-alpha-hydroxyprogesterone
and androstenedione) in many patients. The
substrates for the peripheral enzyme (delta-5-
and DHEAS) are increased because of the
defect in the type II enzyme in steroidogenic
Most patients present as neonates or in early
infancy with clinical manifestations of both
cortisol and aldosterone deficiencies with
feeding difficulties, vomiting, volume depletion,
hyponatremia, and hyperkalemia. Females may
have mild virilization of their external genitalia,
presumably due to excess DHEA, a little of
which is converted peripherally to testosterone.
Males have varying degrees of failure to
normal genital development ranging from
hypospadias to male pseudohermaphroditism
[46 XY disorder of sex development (DSD),
as new nomenclature] with near normal
female external genitalia. However, 3-betahydroxysteroid
dehydrogenase deficiency is
not a common finding in patients who present
with apparent idiopathic hypospadias. In one
study, only 2 out of 90 boys with hypospadias
had evidence of subtle molecular abnormalities
in the 3-beta-hydroxysteroid dehydrogenase
gene. Rarely, patients with severe 3-betahydroxysteroid
dehydrogenase deficiency have
few symptoms and may not be diagnosed
until they seek care for delayed puberty.
Premature pubarche with exaggerated serum
17-alpha-hydroxypregnenolone responses to
ACTH has been described in three girls with
missense mutation of the gene. A late-onset or the non-classic form of 3-beta-hydroxysteroid
dehydrogenase deficiency that causes hirsutism
and menstrual irregularity in adolescent and/or
young adult women has also been described.
The basis for the diagnosis was exaggerated
with serum delta-5-pregnenolone responses to
ACTH, but the validity of these results has
5). Congenital lipoid adrenal hyperplasia:
Congenital lipoid adrenal hyperplasia is the
rarest and usually the most severe form of
adrenal steroidogenesis defect. Congenital lipoid
adrenal hyperplasia is characterized by deficiency
of all adrenal and gonadal steroid hormones,
increased ACTH secretion, and marked adrenal
hyperplasia with progressive accumulation
of cholesterol esters. It is transmitted as an
autosomal recessive trait. It has been thought
that the defect in this disorder would reside
in the CYP11A1 (side chain cleavage) gene.
However, CYP11A1 is required for biosynthesis
of progesterone, and placental progesterone
synthesis is required to maintain pregnancy.
Therefore, complete CYP11A1 deficiency was
thought to be lethal and no homozygous
mutation has been identified in any patient
with congenital lipoid adrenal hyperplasia,.
Subsequently, two patients with congenital
lipoid adrenal hyperplasia have been shown to
have heterozygous mutations of CYP11A1,.
One had apparent haploinsufficiency of
CYP11A1 and the other was a compound
heterozygote with partial inactivation of the
gene. The defect in the majority of patients
within congenital lipoid adrenal hyperplasia
resides in a gene on chromosome 8 that
codes for a protein called the steroidogenic
acute regulatory protein (StAR). StAR is a
mitochondrial phosphoprotein that mediates
the acute response to steroidogenic stimuli
by increasing cholesterol transport from the
outer to the inner mitochondrial membrane-.
StAR is expressed in the adrenal cortex and
gonads but not in the placenta, and for this
reason, placental synthesis of progesterone,
which requires CYP11A1, is unaffected in
congenital lipoid adrenal hyperplasia. The
role of StAR has been studied by sequencing
the gene in patients with congenital lipoid
adrenal hyperplasia-. More than 35 different
mutations have been described; furthermore,
the mutated StAR proteins were inactive
in functional assays. Most of the mutations
reduce activity of the lipid transfer domain
of the StAR protein. Steroidogenic cells that
lacked StAR were initially capable of low levels
of steroidogenesis; this explains why some
steroid hormones may be secreted after puberty.
Bose et al. concluded that the congenital
lipoid adrenal hyperplasia phenotype is the
result of two separate events: 1) the initial
defect in steroidogenesis due to the StAR
mutation, and 2) a subsequent further defect
in steroidogenesis due to cellular damage from
accumulated cholesterol esters. The “two hit”
hypothesis is supported by data from a girl with
a homozygous StAR mutation who underwent
spontaneous puberty at the age of 13.
In mice, with knocked out StAR and
apolipoprotein A-1 genes, the lipid deposits
were composed mostly of high-density
lipoprotein (HDL)-derived cholesterol esters.
The mitochondrial structure of StAR knockout
mice is less abnormal than that of CYP11A1
knockout mice, perhaps because CYP11A1
plays an important role in determining the
morphology of steroidogenic mitochondria.
A patient with male pseudohermaphroditism
(46,XY DSD) and adrenal insufficiency who was
phenotypically similar to patients with StAR
deficiency had a mutation of the SF-1 gene.
Patients with congenital lipoid hyperplasia
caused by StAR mutations typically have
severe adrenal insufficiency very soon after
birth, although they occasionally present later
in infancy, with vomiting, diarrhea, volume
depletion, hyponatremia, and hyperkalemia.
Male infants usually have female external
genitalia due to lack of testicular androgen
production. In comparison, female infants are
normally developed at birth and occasional
patients undergo spontaneous puberty. A
possible explanation for the relative sparing
of ovarian steroid synthesis may be the
dormancy of the ovary until puberty, thereby
preventing the excess cholesterol accumulation
that damages the adrenal glands and testes.
The same explanation may account for the
detectable, if very low, serum aldosterone
concentrations with high plasma rennin activity
in these patients; the adrenocortical cells
destined to become glomerulosa cells are
minimally stimulated in utero. This condition
should be considered in a neonate with any symptoms or signs of adrenal insufficiency
and in male DSD (46,XY DSD). The diagnosis
is confirmed by the absence of demonstrable
steroid biosynthetic activity by either the
adrenals or the gonads. The two patients with
CYP11A1 deficiency presented with adrenal
insufficiency at a later age and did not have
enlarged adrenal glands. One was incompletely
virilized at birth with an XY karyotype and low
levels of all measured steroids when diagnosed
at the age of 4 years. The other patient had
an XX karyotype and presented with adrenal
insufficiency at the age of 9 months.
6). 11-beta-hydroxysteroid dehydrogenase
type 1 (apparent cortisone reductase)
This rare disorder is not a true CAH (i.e., does
not involve a defect in cortisol biosynthesis
but is associated with adrenal hyperplasia
and changes in the cortisol metabolism).
11-Beta-hydroxysteroid dehydrogenase type
1 (HSD11B1) is expressed in certain tissues
such as the liver, adipose tissue, brain, and
adrenal gland, in which it regulates the local
availability of glucocorticoids. Six women and
one boy have been reported to have deficient
expression of this enzyme-. However, no
mutation in the coding regions of the gene was
found, suggesting either that the defect lies
outside the coding region or that some other
abnormality results in inhibition of the function
of the enzyme. The disorder may result from
either an autosomal recessive or an acquired
defect. Additional studies in four patients
demonstrated a triallelic digenic pattern of
inheritance. Each affected individual was
homozygous or heterozygous for two mutations
in intron 3 of the HSD11B1 gene; the other
introns, exons and 1.5 kb of the promoter
region, were normal. In vitro, transcriptional
activation of constructs containing these
mutations was 2.5 times lower than that of
wild type constructs. However, since 25% of
unaffected individuals were heterozygotic for
these mutations and 3% were homozygous,
this mutation alone does not explain the
cortisone reductase deficiency. Each of the
affected individuals, but none of the unaffected
individuals, also had a mutation in exon 5 of the
hexose-6-phosphate dehydrogenase (H6PDH)
gene. Since HSD11B1 requires NADPH for
activity and H6PDH generates NADPH, it is
likely that the combination of mutations led
to cortisone reductase deficiency .
Patients with 11-beta-hydroxysteroid deficiency
present as adolescent or adult women with
truncal obesity, facial plethora, oligomenorrhea,
hirsutism, infertility, and/or acne. One patient
even had a successful pregnancy. Another
six-year-old boy presented with gonadotropinindependent
precocious puberty. The adrenal
glands are diffusely enlarged. Patients with
deficiency in this enzyme have normal serum
cortisol concentrations, high serum adrenal
androgen concentrations, very high urinary
excretion of 5-beta-reduced cortisone metabolites
(tetrahydrocortisone and cortolones), and very
low urinary excretion of cortisol metabolites
(tetrahydrocortisol and cortols), especially the
5-alpha-reduced metabolites. Conversion of
orally administered cortisone to cortisol is
impaired. Adrenal steroidogenesis is suppressed
normally by administration of low-dose
dexamethasone (0.5 mg every 6 hours for 48
Familial Glucocorticoid Resistance:
This is a rare syndrome that is not a true CAH,
but is associated with adrenal hyperplasia and
clinical features similar to those of CYP11B1
(11-beta-hydroxylase) deficiency. Familial
glucocorticoid resistance is inherited as an
autosomal recessive or dominant disorder
characterized by mutations in the glucocorticoid
receptor gene, leading to diminished cortisol
action and secondary stimulation of ACTH
release,. However, some patients with clinical
and biochemical glucocorticoid resistance never
had mutations in the glucocorticoid receptor
gene, indicating the presence of other defects
in the glucocorticoid action.
Glucocorticoid receptor defects include decreased
steroid binding affinity caused by missense
point mutations in the ligand binding domain,
defective nuclear binding caused by a missense
point mutation in the DNA-binding domain
and decreased receptor number caused by a
four-base splice site deletion in exon 6. Mutant
receptors may impair the function of receptors
coded by the normal allele by preventing normal
dimerization or exerting antagonistic effects
on glucocorticoid response elements (GREs),
thereby exerting dominant negative effects that
result in autosomal dominant expression-.
Some of the mutations reduce binding of
the receptor-ligand complex to transcription
factors or co-activators. Patients with familial
glucocorticoid resistance present in childhood to
adulthood with hirsutism, male pattern baldness,
menstrual abnormalities and infertility in
women, isosexual precocious puberty, abnormal
spermatogenesis and infertility in boys, and
with hypertension and hypokalemic alkalosis
in both sexes. The clinical presentation varies
from asymptomatic to severely symptomatic.
Heterozygotes have mild glucocorticoid
resistance but are asymptomatic,,. Plasma
ACTH and serum cortisol concentrations are
increased in this disorder, but maintain their
normal diurnal rhythm-. They are relatively
resistant to suppression with dexamethasone.
Serum concentrations of adrenal androgens
(delta-4-androstenedione, DHEA and its
sulfate [DHEAS]) and of ACTH-dependent
mineralocorticoids (cortisol, corticosterone, and
deoxycorticosterone) are also increased because
of the chronically elevated plasma ACTH
concentration. Serum aldosterone and plasma
rennin activity tend to be decreased. The adrenal
glands appear normal to moderately enlarged.
Symptoms of adrenal insufficiency do not
occur in patients with familial glucocorticoid
resistance because of the compensatory
increases in ACTH and cortisol secretion.
The excess of androgens and mineralocorticoid
can be ameliorated by the administration of
dexamethasone (0.5 to 1.5 mg/day). Thiazide
diuretics administered alone may cause severe
1. White PC, Speiser PW. Congenital adrenal hyperplasia
due to 21-hydroxylase deficiency. Endocr Rev 2000;
2. Pang SY, Wallace MA, Hofman L, et al. Worldwide
experience in newborn screening for classical congenital
adrenal hyperplasia due to 21-hydroxylase deficiency.
Pediatrics 1988; 81: 866-874.
3. Speiser PW, White PC. Congenital adrenal hyperplasia.
N Engl J Med 2003; 349: 776-788.
4. Carroll MC, Campbell RD, Porter RR. Mapping
of steroid 21-hydroxylase genes adjacent to
complement component C4 genes in HLA, the major
histocompatibility complex in man. Proc Natl Acad
Sci U S A 1985; 82: 521-525.
5. White PC, Grossberger D, Onufer BJ, et al. Two genes
encoding steroid 21-hydroxylase are located near the
genes encoding the fourth component of complement
in man. Proc Natl Acad Sci U S A 1985; 82: 1089-
6. White PC, New MI, Dupont B. Structure of human
steroid 21-hydroxylase genes. Proc Natl Acad Sci U
S A 1986; 83: 5111-5115.
7. Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-
Kuriyama Y. Complete nucleotide sequence of two
steroid 21-hydroxylase genes tandemly arranged in
human chromosome: a pseudogene and a genuine
gene. Proc Natl Acad Sci U S A 1986; 83: 2841-2845.
8. New MI, White PC. Genetic disorders of steroid
hormone synthesis and metabolism. Baillieres Clin
Endocrinol Metab 1995; 9: 525-554.
9. Miller WL. Clinical review 54: genetics, diagnosis,
and management of 21-hydroxylase deficiency. J Clin
Endocrinol Metab 1994; 78: 241-246.
10. L’Allemand D, Tardy V, Grüters A, Schnabel D, Krude
H, Morel Y. How a patient homozygous for a 30-kb
deletion of the C4-CYP 21 genomic region can have
a nonclassic form of 21-hydroxylase deficiency. J Clin
Endocrinol Metab 2000; 85: 4562-4567.
11. Miller WL. Gene conversions, deletions, and
polymorphisms in congenital adrenal hyperplasia.
Am J Hum Genet 1988; 42: 4-7.
12. Cooper DN, Ball EV, Krawczak M. The human gene
mutation database. Nucleic Acids Res 1998; 26: 285-
13. Lajić S, Clauin S, Robins T, et al. Novel mutations in
CYP21 detected in individuals with hyperandrogenism.
J Clin Endocrinol Metab 2002; 87: 2824-2829.
14. Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, Otten BJ,
Hermus AR, Sistermans EA. CYP21 gene mutation
analysis in 198 patients with 21-hydroxylase deficiency
in The Netherlands: six novel mutations and a specific
cluster of four mutations. J Clin Endocrinol Metab
2003; 88: 3852-3859.
15. Billerbeck AE, Mendonca BB, Pinto EM, Madureira
G, Arnhold IJ, Bachega TA. Three novel mutations
in CYP21 gene in Brazilian patients with the classical
form of 21-hydroxylase deficiency due to a founder
effect. J Clin Endocrinol Metab 2002; 87: 4314-4317.
16. Speiser PW, Dupont J, Zhu D, et al. Disease expression
and molecular genotype in congenital adrenal
hyperplasia due to 21-hydroxylase deficiency. J Clin
Invest 1992; 90: 584-595.
17. Wedell A, Thilén A, Ritzén EM, Stengler B, Luthman
H. Mutational spectrum of the steroid 21-hydroxylase
gene in Sweden: implications for genetic diagnosis
and association with disease manifestation. J Clin
Endocrinol Metab 1994; 78: 1145-1152.
18. Wilson RC, Mercado AB, Cheng KC, New MI. Steroid
21-hydroxylase deficiency: genotype may not predict
phenotype. J Clin Endocrinol Metab 1995; 80: 2322-
19. Jääskeläinen J, Levo A, Voutilainen R, Partanen J.
Population-wide evaluation of disease manifestation in
relation to molecular genotype in steroid 21-hydroxylase
(CYP21) deficiency: good correlation in a well defined
population. J Clin Endocrinol Metab 1997; 82: 3293-
20. Ordoñez-Sánchez ML, Ramírez-Jiménez S, López-
Gutierrez AU, et al. Molecular genetic analysis of
patients carrying steroid 21-hydroxylase deficiency in
the Mexican population: identification of possible new
mutations and high prevalence of apparent germ-line
mutations. Hum Genet 1998; 102: 170-177.
21. Nimkarn S, Cerame BI, Wei JQ, et al. Congenital
adrenal hyperplasia (21-hydroxylase deficiency) without
demonstrable genetic mutations. J Clin Endocrinol
Metab 1999; 84: 378-381.
22. Koyama S, Toyoura T, Saisho S, Shimozawa K,
Yata J. Genetic analysis of Japanese patients with
21-hydroxylase deficiency: identification of a patient
with a new mutation of a homozygous deletion
of adenine at codon 246 and patients without
demonstrable mutations within the structural gene
for CYP21. J Clin Endocrinol Metab 2002; 87: 2668-
23. Gutai JP, Kowarski AA, Migeon CJ. The detection of
the heterozygous carrier for congenital virilizing adrenal
hyperplasia. J Pediatr 1977; 90: 924-929.
24. Charmandari E, Merke DP, Negro PJ, et al. Endocrinologic
and psychologic evaluation of 21-hydroxylase deficiency
carriers and matched normal subjects: evidence for
physical and/or psychologic vulnerability to stress. J
Clin Endocrinol Metab 2004; 89: 2228-2236.
25. Krone N, Braun A, Roscher AA, Knorr D, Schwarz
HP. Predicting phenotype in steroid 21-hydroxylase
deficiency? Comprehensive genotyping in 155 unrelated,
well defined patients from southern Germany. J Clin
Endocrinol Metab 2000; 85: 1059-1065.
26. Deneux C, Tardy V, Dib A, et al. Phenotype-genotype
correlation in 56 women with nonclassical congenital
adrenal hyperplasia due to 21-hydroxylase deficiency.
J Clin Endocrinol Metab 2001; 86: 207-213.
27. Yanase T, Simpson ER, Waterman MR. 17 alphahydroxylase/
17,20-lyase deficiency: from clinical
investigation to molecular definition. Endocr Rev 1991;
28. Biglieri EG. 17 alpha-Hydroxylase deficiency: 1963-
1966. J Clin Endocrinol Metab 1997; 82: 48-50.
29. Kater CE, Biglieri EG. Disorders of steroid 17 alphahydroxylase
deficiency. Endocrinol Metab Clin North
Am 1994; 23: 341-357.
30. Costa-Santos M, Kater CE, Auchus RJ; Brazilian
Congenital Adrenal Hyperplasia Multicenter Study
Group. Two prevalent CYP17 mutations and genotypephenotype
correlations in 24 Brazilian patients with
17-hydroxylase deficiency. J Clin Endocrinol Metab
2004; 89: 49-60.
31. Zachmann M, Völlmin JA, Hamilton W, Prader A.
Steroid 17,20-desmolase deficiency: a new cause of
male pseudohermaphroditism. Clin Endocrinol (Oxf)
1972; 1: 369-385.
32. Zachmann M, Werder EA, Prader A. Two types of
male pseudohermaphroditism due to 17, 20-desmolase
deficiency. J Clin Endocrinol Metab 1982; 55: 487-490.
33. Winter JS, Couch RM, Muller J, et al. Combined
17-hydroxylase and 17,20-desmolase deficiencies:
evidence for synthesis of a defective cytochrome
P450c17. J Clin Endocrinol Metab 1989; 68: 309-316.
34. Kater CE, Biglieri EG, Brust N, Chang B, Hirai J.
The unique patterns of plasma aldosterone and
18-hydroxycorticosterone concentrations in the
17 alpha-hydroxylase deficiency syndrome. J Clin
Endocrinol Metab 1982; 55: 295-302.
35. Griffing GT, Wilson TE, Holbrook MM, et al. Plasma
and urinary 19-nor-deoxycorticosterone in 17 alphahydroxylase
deficiency syndrome. J Clin Endocrinol
Metab 1984; 59: 1011-1015.
36. Rovner DR, Conn JW, Cohen EL, Berlinger FG, Kem
DC, Gordon DL. 17 alpha-Hydroxylase deficiency. A
combination of hydroxylation defect and reversible
blockade in aldosterone biosynthesis. Acta Endocrinol
(Copenh) 1979; 90: 490-504.
37. D’Armiento M, Reda G, Kater C, Shackleton CH, Biglieri
EG. 17 alpha-hydroxylase deficiency: mineralocorticoid
hormone profiles in an affected family. J Clin Endocrinol
Metab 1983; 56: 697-701.
38. Wit JM, van Roermund HP, Oostdijk W, et al.
Heterozygotes for 17 alpha-hydroxylase deficiency can
be detected with a short ACTH test. Clin Endocrinol
(Oxf) 1988; 28: 657-664.
39. Kagimoto M, Winter JS, Kagimoto K, Simpson ER,
Waterman MR. Structural characterization of normal
and mutant human steroid 17 alpha-hydroxylase genes:
molecular basis of one example of combined 17 alphahydroxylase/
17,20 lyase deficiency. Mol Endocrinol
1988; 2: 564-570.
40. Yanase T, Sanders D, Shibata A, Matsui N, Simpson ER,
Waterman MR. Combined 17 alpha-hydroxylase/17,20-
lyase deficiency due to a 7-basepair duplication in the
N-terminal region of the cytochrome P45017 alpha
(CYP17) gene. J Clin Endocrinol Metab 1990; 70:
41. Yanase T, Kagimoto M, Suzuki S, Hashiba K, Simpson
ER, Waterman MR. Deletion of a phenylalanine
in the N-terminal region of human cytochrome
P-450(17 alpha) results in partial combined 17 alphahydroxylase/
17,20-lyase deficiency. J Biol Chem 1989;
42. Fardella CE, Zhang LH, Mahachoklertwattana P, Lin D,
Miller WL. Deletion of amino acids Asp487-Ser488-
Phe489 in human cytochrome P450c17 causes severe
17 alpha-hydroxylase deficiency. J Clin Endocrinol
Metab 1993; 77: 489-493.
43. Biason A, Mantero F, Scaroni C, Simpson ER, Waterman
MR. Deletion within the CYP17 gene together with
insertion of foreign DNA is the cause of combined
complete 17 alpha-hydroxylase/17,20-lyase deficiency
in an Italian patient. Mol Endocrinol 1991; 5: 2037-
44. Yanase T, Kagimoto M, Matsui N, Simpson ER,
Waterman MR. Combined 17 alpha-hydroxylase/17,20-
lyase deficiency due to a stop codon in the N-terminal
region of 17 alpha-hydroxylase cytochrome P-450. Mol
Cell Endocrinol 1988; 59: 249-253.
45. Rumsby G, Skinner C, Lee HA, Honour JW. Combined
17 alpha-hydroxylase/17,20-lyase deficiency caused by
heterozygous stop codons in the cytochrome P450 17
alpha-hydroxylase gene. Clin Endocrinol (Oxf) 1993;
46. Monno S, Ogawa H, Date T, Fujioka M, Miller WL,
Kobayashi M. Mutation of histidine 373 to leucine
in cytochrome P450c17 causes 17 alpha-hydroxylase
deficiency. J Biol Chem 1993; 268: 25811-25817.
47. Lin D, Harikrishna JA, Moore CC, Jones KL, Miller
WL. Missense mutation serine106----proline causes 17
alpha-hydroxylase deficiency. J Biol Chem 1991; 266:
48. Yanase T, Waterman MR, Zachmann M, Winter JS,
Simpson ER, Kagimoto M. Molecular basis of apparent
isolated 17,20-lyase deficiency: compound heterozygous
mutations in the C-terminal region (Arg(496)----Cys,
Gln(461)----Stop) actually cause combined 17 alphahydroxylase/
17,20-lyase deficiency. Biochim Biophys
Acta 1992; 1139: 275-279.
49. Ahlgren R, Yanase T, Simpson ER, Winter JS, Waterman
MR. Compound heterozygous mutations (Arg 239----
stop, Pro 342----Thr) in the CYP17 (P45017 alpha) gene
lead to ambiguous external genitalia in a male patient
with partial combined 17 alpha-hydroxylase/17,20-
lyasedeficiency. J Clin Endocrinol Metab 1992; 74:
50. Fardella CE, Hum DW, Homoki J, Miller WL. Point
mutation of Arg440 to His in cytochrome P450c17
causes severe 17 alpha-hydroxylase deficiency. J Clin
Endocrinol Metab 1994; 79: 160-164.
51. Yamaguchi H, Nakazato M, Miyazato M, Kangawa
K, Matsukura S. A 5’-splice site mutation in the
cytochrome P450 steroid 17alpha-hydroxylase gene
in 17alpha-hydroxylase deficiency. J Clin Endocrinol
Metab 1997; 82: 1934-1938.
52. Brooke AM, Taylor NF, Shepherd JH, et al. A novel
point mutation in P450c17 (CYP17) causing combined
17alpha-hydroxylase/17,20-lyase deficiency. J Clin
Endocrinol Metab 2006; 91: 2428-2431.
53. Costa-Santos M, Kater CE, Dias EP, Auchus RJ. Two
intronic mutations cause 17-hydroxylase deficiency by
disrupting splice acceptor sites: direct demonstration
of aberrant splicing and absent enzyme activity by
expression of the entire CYP17 gene in HEK-293 cells.
J Clin Endocrinol Metab 2004; 89: 43-48.
54. Arlt W, Walker EA, Draper N, et al. Congenital adrenal
hyperplasia caused by mutant P450 oxidoreductase and
human androgen synthesis: analytical study. Lancet
2004; 363: 2128-2135.
55. Flück CE, Tajima T, Pandey AV, et al. Mutant P450
oxidoreductase causes disordered steroidogenesis with
and without Antley-Bixler syndrome. Nat Genet 2004;
56. Bongiovanni AM, Root AW. The adrenogenital
syndrome. N Engl J Med 1963; 268: 1283-1289.
57. Rhéaume E, Simard J, Morel Y, et al. Congenital adrenal
hyperplasia due to point mutations in the type II 3
beta-hydroxysteroid dehydrogenase gene. Nat Genet
1992; 1: 239-245.
58. Zhang L, Sakkal-Alkaddour H, Chang YT, Yang X, Pang
S. A new compound heterozygous frameshift mutation
in the type II 3 beta-hydroxysteroid dehydrogenase
(3 beta-HSD) gene causes salt-wasting 3 beta-HSD
deficiency congenital adrenal hyperplasia. J Clin
Endocrinol Metab 1996; 81: 291-295.
59. Simard J, Rhéaume E, Leblanc JF, et al. Congenital
adrenal hyperplasia caused by a novel homozygous
frameshift mutation 273 delta AA in type II 3 betahydroxysteroid
dehydrogenase gene (HSD3B2) in three
male patients of Afghan/Pakistani origin. Hum Mol
Genet 1994; 3: 327-330.
60. Simard J, Rheaume E, Mebarki F, et al. Molecular
basis of human 3 beta-hydroxysteroid dehydrogenase
deficiency. J Steroid Biochem Mol Biol 1995; 53: 127-
61. Codner E, Okuma C, Iñiguez G, et al. Molecular study
of the 3 beta-hydroxysteroid dehydrogenase gene type
II in patients with hypospadias. J Clin Endocrinol
Metab 2004; 89: 957-964.
62. Sakai Y, Yanase T, Okabe Y, et al. No mutation in
cytochrome P450 side chain cleavage in a patient with
congenital lipoid adrenal hyperplasia. J Clin Endocrinol
Metab 1994; 79: 1198-1201.
63. Lin D, Gitelman SE, Saenger P, Miller WL. Normal
genes for the cholesterol side chain cleavage enzyme,
P450scc, in congenital lipoid adrenal hyperplasia. J
Clin Invest 1991; 88: 1955-1962.
64. Tajima T, Fujieda K, Kouda N, Nakae J, Miller WL.
Heterozygous mutation in the cholesterol side chain
cleavage enzyme (p450scc) gene in a patient with
46,XY sex reversal and adrenal insufficiency. J Clin
Endocrinol Metab 2001; 86: 3820-3825.
65. Katsumata N, Ohtake M, Hojo T, et al. Compound
heterozygous mutations in the cholesterol side-chain
cleavage enzyme gene (CYP11A) cause congenital
adrenal insufficiency in humans. J Clin Endocrinol
Metab 2002; 87: 3808-3813.
66. Sugawara T, Holt JA, Driscoll D, et al. Human
steroidogenic acute regulatory protein: functional
activity in COS-1 cells, tissue-specific expression,
and mapping of the structural gene to 8p11.2 and a
pseudogene to chromosome 13. Proc Natl Acad Sci
U S A 1995; 92: 4778-4782.
67. Lin D, Sugawara T, Strauss JF 3rd, et al. Role of
steroidogenic acute regulatory protein in adrenal and
gonadal steroidogenesis. Science 1995; 267: 1828-1831.
68. Clark BJ, Wells J, King SR, Stocco DM. The purification,
cloning, and expression of a novel luteinizing hormoneinduced
mitochondrial protein in MA-10 mouse Leydig
tumor cells. Characterization of the steroidogenic acute
regulatory protein (StAR). J Biol Chem 1994; 269:
69. Stocco DM, Ascoli M. The use of genetic manipulation of MA-10 Leydig tumor cells to demonstrate the role
of mitochondrial proteins in the acute regulation of
steroidogenesis. Endocrinology 1993; 132: 959-967.
70. Stocco DM, Sodeman TC. The 30-kDa mitochondrial
proteins induced by hormone stimulation in MA-10
mouse Leydig tumor cells are processed from larger
precursors. J Biol Chem 1991; 266: 19731-19738.
71. Bose HS, Sugawara T, Strauss JF 3rd, Miller WL;
International Congenital Lipoid Adrenal Hyperplasia
Consortium. The pathophysiology and genetics of
congenital lipoid adrenal hyperplasia. N Engl J Med
1996; 335: 1870-1878.
72. Katsumata N, Kawada Y, Yamamoto Y, et al. A novel
compound heterozygous mutation in the steroidogenic
acute regulatory protein gene in a patient with
congenital lipoid adrenal hyperplasia. J Clin Endocrinol
Metab 1999; 84: 3983-3987.
73. González AA, Reyes ML, Carvajal CA, et al. Congenital
lipoid adrenal hyperplasia caused by a novel splicing
mutation in the gene for the steroidogenic acute
regulatory protein. J Clin Endocrinol Metab 2004; 89:
74. Fujieda K, Okuhara K, Abe S, Tajima T, Mukai T, Nakae
J. Molecular pathogenesis of lipoid adrenal hyperplasia
and adrenal hypoplasia congenita. J Steroid Biochem
Mol Biol 2003; 85: 483-489.
75. Bose HS, Pescovitz OH, Miller WL. Spontaneous
feminization in a 46,XX female patient with congenital
lipoid adrenal hyperplasia due to a homozygous
frameshift mutation in the steroidogenic acute
regulatory protein. J Clin Endocrinol Metab 1997;
76. Ishii T, Hasegawa T, Pai CI, et al. The roles of circulating
high-density lipoproteins and trophic hormones in the
phenotype of knockout mice lacking the steroidogenic
acute regulatory protein. Mol Endocrinol 2002; 16:
77. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson
JL. A mutation in the gene encoding steroidogenic
factor-1 causes XY sex reversal and adrenal failure in
humans. Nat Genet 1999; 22: 125-126.
78. Gassner HL, Toppari J, Quinteiro González S, Miller
WL. Near-miss apparent SIDS from adrenal crisis. J
Pediatr 2004; 145: 178-183.
79. Fujieda K, Tajima T, Nakae J, et al. Spontaneous
puberty in 46,XX subjects with congenital lipoid
adrenal hyperplasia. Ovarian steroidogenesis is spared
to some extent despite inactivating mutations in the
steroidogenic acute regulatory protein (StAR) gene. J
Clin Invest 1997; 99: 1265-1271.
80. Pang S, Carbunaru G, Haider A, et al. Carriers for
type II 3beta-hydroxysteroid dehydrogenase (HSD3B2)
deficiency can only be identified by HSD3B2 genotype
study and not by hormone test. Clin Endocrinol (Oxf)
2003; 58: 323-331.
81. Jamieson A, Wallace AM, Andrew R, et al. Apparent
cortisone reductase deficiency: a functional defect in
11beta-hydroxysteroid dehydrogenase type 1. J Clin
Endocrinol Metab 1999; 84: 3570-3574.
82. Draper N, Walker EA, Bujalska IJ, et al. Mutations in the
genes encoding 11beta-hydroxysteroid dehydrogenase
type 1 and hexose-6-phosphate dehydrogenase interact
to cause cortisone reductase deficiency. Nat Genet
2003; 34: 434-439.
83. Małunowicz EM, Romer TE, Urban M, Bossowski A.
11beta-hydroxysteroid dehydrogenase type 1 deficiency
(‘apparent cortisone reductase deficiency’) in a 6-yearold
boy. Horm Res 2003; 59: 205-210.
84. Biason-Lauber A, Suter SL, Shackleton CH, Zachmann
M. Apparent cortisone reductase deficiency: a rare
cause of hyperandrogenemia and hypercortisolism.
Horm Res 2000; 53: 260-266.
85. Phillipov G, Palermo M, Shackleton CH. Apparent
cortisone reductase deficiency: a unique form of
hypercortisolism. J Clin Endocrinol Metab 1996; 81:
86. Charmandari E, Kino T, Chrousos GP. Familial/
sporadic glucocorticoid resistance: clinical phenotype
and molecular mechanisms. Ann N Y Acad Sci 2004;
87. Lamberts SW, Koper JW, Biemond P, den Holder FH,
de Jong FH. Cortisol receptor resistance: the variability
of its clinical presentation and response to treatment.
J Clin Endocrinol Metab 1992; 74: 313-321.
88. Huizenga NA, de Lange P, Koper JW, et al. Five
patients with biochemical and/or clinical generalized
glucocorticoid resistance without alterations in the
glucocorticoid receptor gene. J Clin Endocrinol Metab
2000; 85: 2076-2081.
89. Lamberts SW. The glucocorticoid insensitivity
syndrome. Horm Res 1996; 45: 2-4.
90. Chrousos GP, Vingerhoeds A, Brandon D, et al. Primary
cortisol resistance in man. A glucocorticoid receptormediated
disease. J Clin Invest 1982; 69: 1261-1269.
91. Lamberts SW, Poldermans D, Zweens M, de Jong FH.
Familial cortisol resistance: differential diagnostic and
therapeutic aspects. J Clin Endocrinol Metab 1986; 63:
92. Hurley DM, Accili D, Stratakis CA, et al. Point
mutation causing a single amino acid substitution in
the hormone binding domain of the glucocorticoid
receptor in familial glucocorticoid resistance. J Clin
Invest 1991; 87: 680-686.
[Mail to Editor ]